MYRIAD GENETICS INC — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Q2 2026 revenue declined to $190.7M from $213.1M YoY (11% drop), driven by 9% average revenue per test decline and 1% volume decrease. Prenatal Health revenue fell 16% YoY to $39.8M; Cancer Care Continuum grew 6% in volume but fell 11% in revenue to $114.1M due to reimbursement pressure and unfavorable estimate changes ($11M adjustment). Company lowered full-year 2026 revenue guidance to $770–$790M (from prior implicit higher range), suspended Adjusted EBITDA guidance, and engaged consulting firm for 'Ascend' efficiency initiative.
Why this rating
Revenue decline material (~4% of annual run-rate guidance, ~7.7% of market cap in H1 losses), reimbursement headwinds and margin compression are structural. Nonetheless, company retains $115M cash, business remains operating with modest adjusted free cash burn; not an existential threat given size.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.